Construction of a New Industrial Facility in Gannat

PRESS RELEASE

Unither Pharmaceuticals Launches Construction of a New Industrial Facility in Gannat

Gannat (Allier), January 22, 2026 – The pharmaceutical group Unither Pharmaceuticals is launching the construction of a new industrial facility at its Gannat (Allier) site.

This project represents a total investment of more than €140 million and will lead to the creation of 133 direct jobs by 2028, and nearly 250 jobs by 2030.
It aims to strengthen France’s production capacities for sterile medical devices, in line with an industrial reshoring strategy, healthcare sovereignty, and local economic development.

A facility dedicated to innovative sterile technologies

The future facility will be dedicated to the manufacturing of:

preservative-free sterile multidose systems (PF-MDS), a new activity for the site,
sterile single-dose products using Blow-Fill-Seal (BFS) technology.

The project will enable:

a 40% increase in single-dose production capacity,
an annual capacity of 30 million multidose units,
diversification of the product offering, notably for essential ophthalmic products.

“This investment is fully aligned with our industrial vision: developing sterile solutions that are safe, easy to use, and accessible, in order to make patients’ lives easier,” said Éric Goupil, Chairman and Chief Executive Officer of Unither Pharmaceuticals.

A structuring project for the local economy

Located close to the existing site, the new facility is part of a long-term industrial development strategy for the Bourbonnais region.

Unither is relying on a local ecosystem involving:

the Saint-Pourçain Sioule Limagne Community of Municipalities,
the Allier Department,
local training organizations (IMT, APAVE, vocational high schools) to support skills development and industrial employment.

A project supported by the Auvergne-Rhône-Alpes Region

The project benefits from a €1.5 million grant awarded by the Auvergne-Rhône-Alpes Region under the “Pack Relocalisation – Supporting Industrial Investment” scheme, approved on October 17, 2025.

An industrial partnership for the construction of the building

The design and construction of the building have been entrusted to GSE, a general contractor specialized in complex industrial projects.

The future building, with a surface area of approximately 20,000 m², will include ISO 5, 6 and 7 cleanrooms, laboratories, storage areas, and offices. It will meet regulatory requirements (ISO 13485, GMP) and incorporate RE2020 environmental standards, including a 700 kWp photovoltaic power plant.

“This project makes it possible to deploy an ambitious environmental approach, integrating energy performance and low-carbon solutions, while meeting the stringent requirements of a pharmaceutical industrial site,” emphasized Liès Branche, Director, GSE Regions.

Timeline

Start of construction: March 2025
Completion of construction: December 2026
Start of industrial operations: from 2028
First commercial launches: 2029

ABOUT UNITHER PHARMACEUTICALS

Unither Pharmaceuticals is an international pharmaceutical contract development and manufacturing organization (CDMO), specialized in liquid formulations in single-dose and multidose formats.

The Group employs 2,300 people and operates eight manufacturing sites in France, the United States, Brazil, and China, as well as an R&D center in France. In 2024, Unither Pharmaceuticals generated revenues of €522 million.

More information: https://www.unither-pharma.fr/

ABOUT GSE

Founded in 1976, GSE is a specialist in commercial real estate and turnkey industrial construction projects.

More information: https://www.gsegroup.com/

PRESS CONTACT

Unither Pharmaceuticals – Elisabeth Alidou
Head of Communications
press@unither-pharma.com //
www.unither-pharma.com